Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Drugs in Space III: Chiron's PEG-IL-2, Schering's Intron A among experiments on board the shuttle Discovery.

  • News

Executive Summary

DRUGS IN SPACE III: CHIRON's PROLEUKIN PEG-IL-2 is among the drug compounds that will be tested in SPACEHAB-3 aboard the NASA shuttle Discovery, which launched from the Kennedy Space Center on Feb. 3. The "IMMUNE-2" experiment will test treatment of immune system deficiencies in rats administered Proleukin PEG-IL-2 (polyethylene glycosylated-interleukin-2) as a possible treatment for AIDS and other immunosuppresive diseases. Both IL-2 and PEG-IL-2 are in clinical trials for AIDS. PEG-IL-2, whose duration of effect is 10-fold longer than IL-2, is approved for refractory renal cancer.

Table

View full table

Tags:
Latest Headlines

What’s The Key To Successful R&D With Artificial Intelligence? ‘Bilingual’ Scientists

Pink Sheet Podcast: US FDA Adcomm Reform, Clinical Trial Modeling Boost, AI For Drug Review

US FDA Inspectors, Product Centers Working Closer Together Ahead Of ORA Reorg

Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs

See All
UsernamePublicRestriction

Register

PS025683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By